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Objective. To explorewhether it is safe to change from transecting excision andprimary anastomosis (tEPA) towards nontransecting
excision and primary anastomosis (ntEPA) in the treatment of short bulbar urethral strictures and to evaluate whether surgical
outcomes are not negatively affected after introduction of ntEPA.Materials and Methods. Two-hundred patients with short bulbar
strictures were treated by tEPA (n=112) or ntEPA (n=88) between 2001 and 2017 in a single institution. Failure rate and other
surgical outcomes (complications, operation time, hospital stay, catheterization time, and extravasation at first cystography) were
calculated for both groups. Potentially predictive factors for failure (including ntEPA) were analyzed using Cox regression analysis.
Results. Median follow-up for the entire cohort was 76 months, 118 months, and 32 months for, respectively, tEPA and ntEPA
(p<0.001). Nineteen (9.5%) patients suffered a failure, 13 (11.6%) with tEPA and 6 (6.8%) with ntEPA (p=0.333). High-grade (grade
≥3) complication rate was low (1%) and not higher with ntEPA.Median operation time, hospital stay, and catheterization time with
tEPA and ntEPA were, respectively, 98 and 87 minutes, 3 and 2 days, and 14 and 9 days. None of these outcomes were negatively
affected by the use of ntEPA. Diabetes and previous urethroplasty were significant predictors for failure (Hazard ratio resp. 0.165
and 0.355), whereas ntEPAwas not.Conclusions. Introduction of ntEPA did not negatively affect short-term failure rate, high-grade
complication rate, operation time, catheterization time, and hospital stay in the treatment of short bulbar strictures. Diabetes and
previous urethroplasty are predictive factors for failure.
1. Introduction
The International Consultations on Urologic Diseases
(ICUD) recommends urethroplasty by excision and primary
anastomosis (EPA) for short and isolated bulbar urethral
strictures as it provides an excellent success rate (93.8%)
with a low complication rate [1]. After EPA, the diseased
segment is entirely removed and replaced by own healthy
urethra without the need for urethral substitution material
(grafts or flaps), which is probably the reason for the high
success rate. During the “classic” transecting EPA (tEPA), the
corpus spongiosum containing the urethra is transected full
thickness at the level of the stricture [2]. As EPA only requires
excision of the narrowed urethra and the surrounding
spongiofibrosis, a full thickness transection is usually not
necessary. To avoid this and to preserve the dual blood
supply of the urethra, Jordan et al. introduced the concept
of vessel-sparing or nontransecting EPA (ntEPA) [3], later
slightly modified by Andrich et al. [4]. This nontransecting
variant is an attempt to reduce the surgical trauma of tEPA
and several centers have introduced this technique in their
reconstructive repertoire[4–6]. A prerequisite to use ntEPA
is that the outcomes are at least not inferior compared
to the standard technique of tEPA. Case series of ntEPA
have a promising short-term success rate of 94.5-100%
[3, 5–7], which is in line with the composite success rate
of 93.8% for the tEPA reported by the ICUD[1]. However,
indirect comparison of series is hazardous as patient and
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stricture characteristics, follow-up schedules, and reporting
of outcomes might vary among series.Therefore, the primary
objective of this study is to evaluate whether the change in
practice from tEPA to ntEPA yielded surgical outcomes that
are not inferior to the patient. To the best of our knowledge,
this is the first paper to report this.
2. Material and Methods
2.1. Study Population. A database was collected of all male
patients (n=852)who underwent urethroplasty at Ghent Uni-
versity Hospital starting from 2001 (start of electronic med-
ical file). Since 2008, this collection was done prospectively.
Patients who underwent EPA, either by the transecting or
nontransecting technique, for isolated short bulbar strictures
(ranging from the penoscrotal angle up to the urogenital
diaphragm) were selected from this database until December
2017. Exclusion criteria were EPA performed for posterior
or penile strictures, EPA with concomitant urethroplasty at
another part of the urethra, EPA in transgender patients,
and EPA in patients on clean intermittent catheterization. All
patients underwent preoperative evaluation including history
taking (with emphasis on stricture etiology and previous
urethral interventions), clinical examination, uroflowmetry,
and urethrography. According to our in-home algorithm to
treat urethral strictures, EPA is the preferred technique for
short (≤3cm) bulbar strictures [8]. After attendance at a
masterclass on urethroplasty we became familiar with the
technique and being convinced of the theoretical advantages
of ntEPA, we performed our first cases in November 2011.
Starting from January 2012, ntEPA became the standard
technique.
2.2. Surgical Technique. A detailed description of the oper-
ative techniques is beyond the scope of this article as it has
been published previously [6, 9]. In brief, the patient is placed
in the social lithotomy position, a midline perineal incision
is made, and the bulbospongiosus muscle is incised at the
midline and dissected away from the corpus spongiosum
containing the bulbar urethra. The bulbar urethra is circum-
ferentially detached from the corporal bodies and mobilized
from the penoscrotal angle up to the urogenital diaphragm.
With tEPA, the perineal body (“centrum tendineum”) is
incised for further mobilization of the ventral bulbar urethra.
With this technique, the spongious tissue is transected full
thickness at the level of the stricture which is marked after
introduction of a metal sound through the meatus. The
narrowed urethra and surrounding spongiofibrosis are fully
excised, the healthy urethral ends are spatulated, and a
tension-free anastomosis is made by 8 resorbable sutures 4.0.
For ntEPA, the modification described by Andrich et al. was
used [4]. The urethra is incised dorsally at the level of the
stricture. Again, the stricture and surrounding fibrosis are
excised but with preservation of the ventral spongiosum.The
urethral edges are also spatulated and connected end-to-end
with 8 resorbable sutures 4.0. In case of any difficulties to
ensure a complete resection of the fibrosis or if the fibrosis
encompasses the entire thickness of the spongious tissue,
conversion to tEPA is done. The spongious tissue is closed
with resorbable sutures 4.0 over the urethral anastomosis.
This second layer (“spongioplasty”) is circumferential with
tEPA and at the dorsolateral side with ntEPA. For both
techniques, a 20Fr silicone catheter is left in place as well as a
perineal suction drain.
2.3. Follow-Up and Evaluation. The suction drain is removed
after 24-48 hours. The patient is discharged when his clinical
condition allows for it, which is usually after 2 days. The
catheter is removed 1 to 2 weeks later on ambulatory base
if voiding cystourethrography confirms absence of extrava-
sation [10]. In case of extravasation, the examination is
repeated after one week. Follow-up including history taking
and uroflowmetry was advised every 3 months during the
1st year, and annually thereafter. Surgical complications
(≤90 days) were scored according to the Clavien-Dindo
classification. Patients were asked to come on earlier visit
if they experience obstructive urinary symptoms or had a
urinary tract infection. In case of suspicion of recurrence
(clinical symptoms or maximum urinary flow <15ml/s),
retrograde urethrography or urethroscopy was performed.
Referred patientswere sent back to and followed by their local
urologist. A functional definition of failure was used, namely,
obstructive symptoms with the need for additional urethral
instrumentation (including simple dilation) [11]. Other sur-
gical outcomes analyzed are operation time, hospital stay,
catheterization time, and extravasation at first cystography.
Functional outcomes (incontinence, erectile function, and
genital sensitivity) are not the scope of this study as these
parameters were not systematically questioned and in those
where it was done, different questionnaireswere used over the
years. The study was approved by the local ethics committee
(EC UZG 2008/234). All operations were done by 2 surgeons
(W.O., N.L.).
2.4. Statistical Analysis. A first analysis was done per surgical
technique (tEPA versus ntEPA). As mentioned above, since
2012 ntEPA became the standard technique. However, in
case of difficulties or severe spongiofibrosis, conversion to
tEPA was possible. As these are presumably more complex
cases, a selection bias between surgical groups since 2012 is
imminent. In order to minimize this, a second analysis was
done using the intention-to-treat (ITT) principle in which
all conversions to tEPA since 2012 remained classified as
ntEPA cases (further called “ITT-ntEPA”). Statistical tests
were done using IBM SPSS software version 25.0. All tests
were done 2-sided and a p value <0.05 indicates statistical
significance. Next to descriptive statistics, categorical vari-
ables were compared using Fischer’s exact test. Continuous
variables were analyzed for parametric distribution using
the Shapiro-Wilk test and as all variables had a nonpara-
metric distribution, the Mann-Whitney U test was used
for comparison. Failure-free survival (FFS) was calculated
using Kaplan-Meier survival analysis with log rank statistics.
To evaluate whether ntEPA was an independent predictor
for failure, uni- and multivariate Cox regression analysis
with calculation of the Hazard Ratio (HR) was performed.
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Table 1: Patient and stricture characteristics (IQR: interquartile range; tEPA: transecting excision and primary anastomosis; ntEPA:
nontransecting excision and primary anastomosis).
Total (n=200) tEPA (n=112) ntEPA (n=88) p-value
age (years); median (IQR) 49 (32-65) 49 (34-66) 47 (30-64) 0,216
follow-up (months); median
(IQR) 76 (32-122) 118 (93-148) 32 (17-57) <0,001
stricture length (cm); median
(IQR) 1,5 (1-2) 1,5 (1-2) 1,25 (1-2) 0,004
diabetes; n(%) 11 (5,5%) 6 (5,4%) 5 (5,7%) 1
presence of suprapubic catheter;
n(%) 44 (22%) 29 (25,9%) 15 (17%) 0,169
previous urethroplasty; n(%) 37 (18,5%) 19 (17%) 18 (20,5%) 0,584
etiology; n(%)
idiopathic/congenital 102 (51%) 52 (46,4%) 50 (56,8%)
0,508iatrogenic 72 (36%) 43 (38,4%) 29 (33%)
external trauma 20 (10%) 13 (11,6%) 7 (8%)
inflammatory 6 (3%) 4 (3,6%) 2 (2,3%)
Table 2: Surgical outcome per surgery technique (IQR: interquartile range; FFS: failure-free survival; tEPA: transecting excision and primary
anastomosis; ntEAP: nontransecting excision and primary anastomosis).
Total (n=200) tEPA (n=112) ntEPA (n=88) p-value
operation time (mintues); median
(IQR) 92 (79-108) 98 (80-115) 87 (71-100) <0,001
hospital stay (days); median (IQR) 2 (2-3) 3 (2-4) 2 (1-2) <0,001
extravasation at first cystography;
n(%) 12 (6%) 6 (5,4%) 6 (6,8%) 0,768
catheterization time (days); median
(IQR) 13 (9-14) 14 (13-15) 9 (8-13) <0,001
complications; n(%)
none 170 (85%) 100 (89,3%) 70 (79,5%)
0,147G1 20 (10%) 8 (7,1%) 12 (13,6%)
G2 8 (4%) 3 (2,7%) 5 (5,7%)
G3 2 (1%) 1 (0,9%) 1 (1,1%)
Failure, n(%) 19 (9,5%) 13 (11,6%) 6 (6,8%) 0,333
Estimated failure free survival, % (standard deviation)
1y-FFS 97 (±1,2)% 98,2 (±1,3)% 95,5 (±2,2)%
0,3563y-FFS 95,2 (±1,6)% 95,5 (±2)% 95,5 (±2,2)%
10y-FFS 85,6 (±3,5)% 86,9 (±3,7)% NR
The following variables were included: type of urethroplasty
(tEPA versus ntEPA), previous urethroplasty, presence of
suprapubic catheter, stricture length, and diabetes. For every
surgical parameter (failure rate, complication rate, operation
time, hospital stay, extravasation at first cystography, and
catheterization time) the null hypothesis (H
0
) was as follows:
“the surgical parameter is not worse with ntEPA compared to
tEPA.”
3. Results
3.1. Per Surgery Analysis. A total of 200 patients underwent
EPA, 112 by tEPA and 88 by ntEPA. Median follow-up for
the entire cohort was 76 months, with a significant longer
follow-up for tEPA compared to ntEPA (resp., 118 versus
32 months; p<0.001). There were no significant differences
between both groups for patient’s age, presence of diabetes,
stricture etiology, presence of a suprapubic catheter, and
previous urethroplasty (Table 1).Median stricture length with
tEPA and ntEPA was 1,5 and 1,25 cm, respectively (p=0.004).
The following hypotheses concerning surgical outcomes were
evaluated (Table 2).
3.1.1. 𝐻0: Operation Time Is Not Longer with ntEPACompared
to tEPA. Median operation time with tEPA and ntEPA was,
respectively, 98 and 87minutes (p<0.001).Thenull hypothesis
cannot be rejected.
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Table 3: Surgical outcome per intention-to-treat cohort (IQR: interquartile range; FFS: failure-free survival; ITT-tEPA: intention-to-treat
transecting excision and primary anastomosis; ITT-ntEAP: intention-to-treat nontransecting excision and primary anastomosis; NA: not
available).
ITT-tEPA
(n=101)
ITT-ntEPA
(n=99) p-value
follow-up (months); median (IQR) 122 (97-150) 33 (17-59) <0,001
age (years); median (IQR) 50 (34-67) 44 (31-63) 0,102
stricture length (cm); median (IQR) 1,5 (1-2) 1,5 (1-2) 0,07
diabetes; n(%) 6 (5,9%) 5 (5,1%) 1
presence of suprapubic catheter;
n(%) 26 (25,7%) 18 (18,2%) 0,233
operation time (minutes); median
(IQR) 95 (80-110) 88 (73-100) 0,009
previous urethroplasty; n(%) 15 (14,9%) 22 (22,2%) 0,205
hospital stay (days); median (IQR) 3 (2-4) 2 (1-2) <0,001
extravasation at first cystography;
n(%) 4 (4%) 8 (8,1%) 0,248
catheterisation time (days); n(%) 14 (13-14) 9 (8-14) <0,001
failure; n(%) 12 (11,9%) 7 (7,1%) 0,336
complications; n(%)
none 92 (91,1%) 78 (78,8%)
0,024G1 7 (6,9%) 13 (13,1%)
G2 1 (1%) 7 (7,1%)
G3 1 (1%) 1 (1%)
Estimated failure free survival, % (standard deviation)
1y-FFS 98 (±1,4)% 96 (±2)%
0,2563y-FFS 95 (±2,2)% 96 (±2)%
10y-FFS 87,4 (±3,7)% NA
3.1.2. 𝐻0: Hospital Stay Is Not Longer with ntEPA Compared
to tEPA. Patients treated by tEPA had a median hospital stay
of 3 days compared to 2 days with ntEPA (p<0.001).The null
hypothesis cannot be rejected.
3.1.3. 𝐻0: ntEPA Is Not Associated with More Extravasa-
tion at First Cystography Compared to tEPA and There Is
No Longer Catheterization Time with ntEPA Compared to
tEPA. Extravasation at first cystography requiring catheter
reinsertion was observed in 5.4% and 6.8% of patients
treated, respectively, by tEPA and ntEPA (p=0.768). Median
catheterization time with tEPA and ntEPA was, respectively,
14 and 9 days (p<0.001). The null hypothesis cannot be
rejected.
3.1.4. 𝐻0: ntEPA Is Not Associated with More Complications
Compared to tEPA. No complications were reported in 89.3
and 79.5% for, respectively, tEPA and ntEPA (p=0.147). Low-
grade complication rate was not significantly different among
groups. Two patients (1%) suffered a grade 3 complication
(requiring intervention), one in each group.The null hypoth-
esis cannot be rejected.
3.1.5. 𝐻0: ntEPA Has No Higher Failure Rate Compared to
tEPA. 13 (11.6%) and 6 (6.8%) patients, respectively, suffered a
failure with tEPA and ntEPA (p=0.333).The estimated 1- and
3-year FFS is 98.2 and 95.5% for tEPA and 95.5 and 95.5%
for ntEPA (p=0.356) (Table 2).The null hypothesis cannot be
rejected.
3.2. Intention-to-Treat (ITT) Analysis. Patient and stricture
characteristics did not significantly differ between these 2
cohorts (Table 3). Asmentioned above, all patients in the ITT-
tEPA cohort (n=101) underwent tEPA. However, conversion
towards tEPA was performed in 11 of 99 (11.1%) patients of
the ITT-ntEPA cohort. Table 4 provides information about
the characteristics of the patients converted to tEPA and
those treated by ntEPA. In the ITT-ntEPA cohort, patients
finally treated with tEPA had a median stricture length of
2 cm compared to 1,25 cm for ntEPA (p=0.019) whereas other
preoperative characteristics were comparable. Median oper-
ation time for ITT-tEPA and ITT-ntEPA was, respectively,
95 and 88 minutes (p<0.009). in the ITT-ntEPA cohort,
patients finally treated by tEPA had a median operation time
of 155 minutes compared to 87 minutes with ntEPA (p=0.01).
Median hospital stay was 3 and 2 days for, respectively, ITT-
tEPA and ITT-ntEPA (p<0.001). In the ITT-ntEPA cohort,
patients finally treated by tEPA and ntEPA both had a
median hospital stay of 2 days (p=0.088). Extravasation at
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Table 4: Characteristics and surgical outcomes of patients treated by tEPA and ntEPA in the intention-to-treat ntEPA cohort (IQR:
interquartile range; FFS: failure-free survival; ITT-tEPA: intention-to-treat transecting excision and primary anastomosis; ITT-ntEAP:
intention-to-treat nontransecting excision and primary anastomosis; NA: not available).
tEPA (n=11) ntEPA (n=88) p-value
follow-up (months); median (IQR) 36 (23-73) 32 (17-57) 0,308
age (years); median (IQR) 44 (36-52) 47 (30-64) 0,676
stricture length (cm); median (IQR) 2 (1,25-2,5) 1,25 (1-2) 0,019
diabetes; n(%) 0 (0%) 5 (5,7%) 1
presence of suprapubic catheter;
n(%) 3 (27,3%) 15 (17%) 0,415
previous urethroplasty; n(%) 4 (36,5%) 18 (20,5%) 0,256
operation time (minutes); median
(IQR) 115 (88-158) 87 (71-100) 0,01
hospital stay (days); median (IQR) 2 (2-3) 2 (1-2) 0,088
extravasation at first cystography;
n(%) 2 (18,2%) 6 (6,8%) 0,217
catheterization time (days); median
(IQR) 15 (12-15) 9 (8-13) 0,005
failure; n(%) 1 (9,1%) 6 (6,8%) 0,574
complications; n(%)
none 8 (72,7%) 70 (79,5%)
0,339G1 1 (9,1%) 12 (13,6%)
G2 2 (18,2%) 5 (5,7%)
G3 0 (0%) 1 (1,1%)
Table 5: Uni-andmultivariate Cox regression analysis to predict for failure (HR: Hazard Ratio; CI: confidentiality interval; tEPA: transecting
excision and primary anastomosis; ntEPA: nontransecting excision and primary anastomosis).
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
type of urethroplasty (tEPA vs
ntEPA) 0,593 0,193-1,822 0,361 0,671 0,212-2,122 0,497
previous urethroplasty (no
versus yes) 0,368 0,139-0,973 0,044 0,355 0,130-0,970 0,043
suprapubic catheter (no versus
yes) 1,613 0,469-5,539 0,448 1,468 0,409-5,259 0,556
Stricture length 0,784 0,383-1,605 0,505 0,743 0,340-1,623 0,456
diabetes (no versus yes) 0,185 0,053-0,651 0,009 0,165 0,046-0,596 0,006
first cystography was reported in 4% and 8.1% of ITT-
tEPA and ITT-ntEPA cases, respectively (p=0.248). Median
catheterization time with ITT-tEPA and ITT-ntEPA was,
respectively, 14 and 9 days (p<0.001). In the ITT-ntEPA
cohort, patients treated by tEPA had a longer catheterization
time compared to ntEPA (15 versus 9 days; p=0.005). More
low-grade (G1-G2) complications were reported in the ITT-
ntEPA cohort compared to ITT-tEPA (20,2% versus 7,9%;
p=0.024). In the ITT-ntEPA cohort, patients finally treated by
tEPA had a complication rate of 27,3% compared to 20,5% for
patients treated by ntEPA (p=0.339). 12 (11.9%) and 7 (7.1%)
patients, respectively, suffered a failure with ITT-tEPA and
ITT-ntEPA (p=0.336).The estimated 1- and 3-year FFS are 98
and 95% for tEPA and 96 and 96% for ntEPA (p=0.256).
3.3. Additional Analyses. In total, 19 (9.5%) patients suffered
a failure. Of the 19 failed cases, 6 (31.6%) cases were observed
within the 1st year, 6 (31.6%) between the 2nd and 5th year and
7 (36.8%) after the 5th postoperative year. For tEPA, 2 (15.4%),
4 (30,8%), and 7 (53,8%) failures were detected within the
1st year, between the 2nd and 5th year, and after 5 years,
respectively. For ntEAP, 4 (66.7%) cases were detected during
the 1st year after operation and 2 (33.3%) between the 2nd and
5th year.
Cox regression analysis could not identify ntEPA as a
predictor for failure (Table 5). In univariate analysis, pre-
vious urethroplasty (HR 0.369; p=0.044) and diabetes (HR
0.185; p=0.009) were predictive for failure. Both previous
urethroplasty (HR 0.355; p=0.043) and diabetes (HR 0.165;
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p=0.006) remained negative predictive factors inmultivariate
analysis.
4. Discussion
The success rate of 88.4% for tEPA in this series might appear
somewhat lower compared to the 93.8% composite success
rate for tEPA reported in the ICUD-review [1]. However, the
median follow-up of 115 months in this paper is substantially
longer compared to the papers included in that review [1].
Andrich et al. reported an 87% success rate after 10-year
follow-up [12]. Although this series reported durable results
on the long termwith most of the recurrences occurring with
the first years after surgery [12], this could not be confirmed
by the present series as 53.8%of failureswith tEPAwere found
even after the 5th postoperative year. In two other series,
where time-related events are available, a steady decline in
the success rate of tEPA was observed as well [13, 14]. As
for substitution urethroplasty, this indicates that EPA also
needs prolonged follow-up as late recurrences are possible.
Some of our late failures were detected on occasion in an
asymptomatic patient for which access to the bladder was
needed (e.g., urethral catheter during surgery and cystoscopy
because of hematuria). It has indeed been described that
a stricture only becomes symptomatic once the urethral
diameter is less than 10Fr. It is likely that a strict follow-up
schedule with standard cystoscopy would have detected these
failures earlier [11]. Some of the late failures might also be
attributed to progression of the stricture disease as almost
20% of patients already underwent previous urethroplasty.
The shorter follow-up with ntEPA in this series is explained
by the change in practice since 2012 where it became the
standard technique. The 93.2% success rate with ntEPA is in
linewith previous reports [3–7]. Estimated 1- and 3-FFS could
not demonstrate inferiority of ntEPA versus tEPA nor could
uni- and multivariate Cox regression analysis identify ntEPA
as an independent predictive factor for failure. With ntEPA, 2
failures were detected between the 2nd and 5th postoperative
year, also underlining the need for prolonged follow-up to
evaluate whether this noninferiority remains on the long
term (>5 years follow-up). With ntEPA, the operation time
was on average 11 minutes shorter. With ntEPA, no need for
ventral dissection deeper than the perineal body is needed
which saves time. Furthermore, full transection of the corpus
spongiosum with tEPA leads to substantial bleeding through
the bulbar arteries with need for additional hemostasis (and
time to achieve this). On the other hand, we perceive that the
anastomosis itself is somewhat more difficult to perform and
more time-consuming with ntEPA. However, other factors
might bias operation time. By the standard introduction of
ntEPA in 2012, both surgeons already had a large experience
with urethral anatomy and urethroplasty. This experience
probably has facilitated the introduction of ntEPA. In the
earlier stages when uniformly tEPA was performed, this
experience was less and surgery could have taken more time.
Furthermore, since 2012 an important selection bias is present
at the expense of tEPA: the more complex cases are still
treated with tEPA and this complexity might account for a
longer operation time. Nevertheless, even with ITT-analysis,
operation time remained in favor of ntEPA. At least, this
indicates that a shift in practice towards the use of ntEPA
does not negatively affect operation time in surgeons already
proficient with tEPA.Themore complex nature of tEPA cases
since 2012 might also be apparent by the longer stricture
length and the longer catheterization time compared to the
contemporary ntEPA cases. This selection bias might be the
reason why strictures treated by ntEPA were shorter in the
per surgery analysis but no longer in the ITT-analysis. This
selection bias might in part explain the longer catheterization
time with tEPA. However, the longer catheterization time
is undoubtedly related to a change in our practice for
catheter stay since 2010 when it was decided to remove the
catheter after 1 week for simple cases (whereas this was 2
weeks before) [10]. With ntEPA, a one-day shorter hospital
stay was observed. Although this might indicate a quicker
recovery with ntEPA, this cannot by assumed as such. In
recent years, budgetary reasons have urged us to discharge
the patients as early as possible which probably attributed
towards the shorter hospital stay since 2012. The observation
that the tEPA cases since 2012 had an equal hospital stay
despite a probably more complex stricture supports the latter
hypothesis. The complication rate in this series is low and
confirms the finding of other colleagues [5, 14]. High-grade
(≥grade 3) complicationswere notmore frequentwith ntEPA.
With ITT-analysis (but not per surgery analysis), low-grade
complications were somewhat more frequent with ntEPA.
This is likely due to the mainly retrospective data collection
with risk of underreporting of low-grade complications in
tEPA versus the prospective data collection with ntEPA.
Nevertheless, this observation must raise a concern and
warrants further evaluation.
Despite introduction of ntEPA, we needed to convert
towards a tEPA in approximately 10% of cases. A more distal
location of the stricture within the bulbar urethra was not
a reason for conversion to tEPA in this series. The main
reason for conversion was extensive spongiofibrosis (“full
thickness”) in which it was no longer valuable to spare the
ventral spongious tissue. This conversion to tEPA is not
at all jeopardized by an approach to go for ntEPA as all
initial surgical steps are the same. From this series, it is
clear that tEPA must remain in the repertoire of the urethral
surgeon. Furthermore, tEPA remains indispensable in the
delayed treatment of pelvic fracture related injuries [15, 16]
and iatrogenic posterior urethral injuries [17]. However, the
applicability of ntEPA for posterior strictures is currently
explored as well [6, 18].
The aim of ntEPA is to reduce the surgical trauma with
preservation of the dual blood supply of the urethra. This
might offer an advantage for subsequent urethral interven-
tions, e.g., redo-urethroplasty with free graft in which a
well-vascularized graft bed is essential or implantation of
an artificial urinary sphincter with less risk of cuff erosion
[3]. Furthermore, ntEPA might offer a benefit regarding
the reported vascular deficiency of the glans penis and
the risk of erectile dysfunction with tEPA [19, 20]. The
present dataset lacks information to evaluate these potential
advantages. Nevertheless, despite the theoretical benefit, at
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least a transient decline in erectile function in 6-21.9%of cases
has already been reported with ntEPA as well [4–7].
Diabetes and previous urethroplasty were identified as
independent predictors for failure. With both techniques
of EPA and the associated need for extensive mobilization
of the bulbar urethra, the “3th” vascular supply (small
arterial connections between the corporal bodies and the
corpus spongiosum) of the urethra is sacrificed. Diabetes
with its associated microangiopathy further increases the
risk of ischemia at the urethral ends which is a reason for
failure of the anastomosis [21]. In addition, diabetes might
be a contributing factor in the development of ischemic
strictures, which might explain some late failures. Diabetes
as risk factor for failure was identified by another series
as well [21]. A previous failed urethroplasty usually reflects
a more complex urethral pathology with a higher risk of
failure [22]. EPA for a failure after previous urethroplasty
is possible in case of a previous EPA in which the urethral
mobilization was insufficient for tension-free anastomosis
(technical error). EPA is also possible for a short recurrence
after graft urethroplasty, usually at one of the ends of the graft
[23]. Other series have also identified previous urethroplasty
as a negative predictive factor [14, 21], whilst others have not
[23].
This study has several limitations. Until 2008, data collec-
tion was retrospective with its inherent risk of bias. Although
a follow-up schedule is proposed to the patients and the refer-
ring urologists, this is not systematically followed.This might
also explain delayed detection of failure or underreporting
of (minor) complications. A functional definition of failure
was used, but at the moment, an anatomical definition is
advised as it is more accurate and objective [11]. Validated
patient reported outcome measures as suggested by Jackson
et al. [24] were not systematically used, as it lasted to 2017
until a Dutch validation was available [25].This prohibits any
meaningful further evaluation. The follow-up of ntEPA is rel-
atively short. Another important limitation is that this paper
is an evaluation of basically 2 noncontemporary cohorts.
Changes in practice, increasing surgical experience, selection
of more challenging cases, etc. might have a major impact
on outcome parameters. Therefore, any direct comparison
of these 2 cohorts must be avoided. To overcome all the
above-mentioned shortcomings, it is necessary to conduct a
prospective randomized study comparing tEPA with ntEPA
evaluating surgical and functional outcomes using a strict
protocol. Because important surgical parameters were not
negatively affected in this series after introduction of ntEPA,
it appears justified to start up such a trial. In this perspective
and to elucidate the definitive role of ntEPA, our center has
initiated the VeSpAR-trial: a prospective randomized con-
trolled trial comparing Vessel-Sparing Anastomotic Repair
and transecting anastomotic repair in isolated short bulbar
urethral strictures (ClinicalTrials.gov NCT03572348).
5. Conclusion
Introduction of ntEPA for short bulbar strictures by experi-
enced urethral surgeons does not negatively affect short-term
failure rate, high-grade complication rate, operation time,
hospital stay, and catheterization time. Late recurrences are
possible with both types of EPA underlining the need for
continued follow-up in these patients. tEPA must remain in
the surgical repertoire for challenging cases. Diabetes and
previous urethroplasty are independent predictors for failure
of EPA.
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